Episode Details
Back to Episodes
Wegovy on Pharmac's Options: A Game-Changer for Obesity Care?
Description
Pharmacs inclusion of Wegovy in its Options for Investment list could pave the way for funding the weight loss drug semaglutide, potentially benefiting New Zealanders battling obesity. This move, targeting those with a BMI over fifty or thirty-five with related health issues, could extend coverage to teens over twelve, unlike stricter rules in Australia. Despite the drugs high cost, experts like pediatric endocrinologist Wayne Cutfield and weight loss doctor Gerard McQuinlan see potential in its ability to manage conditions like high blood pressure, sleep apnea, and diabetes, possibly reducing overall health costs. With specialists advocating for full coverage at a five-dollar prescription fee, this development could significantly impact obesity care in New Zealand.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/10cd459c0fee4727